首页> 外文期刊>Vaccine >Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization.
【24h】

Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization.

机译:图拉弗朗西斯菌的新减毒靶向缺失突变体SCHU S4的区别能力对小鼠抵抗强毒细菌气溶胶攻击的区分能力:宿主背景和免疫途径的影响。

获取原文
获取原文并翻译 | 示例
       

摘要

Francisella tularensis subspecies tularensis is a highly virulent facultative intracellular pathogen of humans and a potential biological weapon. A live vaccine strain, F. tularensis LVS, was developed more than 50 years ago by pragmatic attenuation of a strain of the less virulent holarctica subspecies. LVS was demonstrated to be highly effective in human volunteers who were exposed to intradermal challenge with fully virulent subsp. tularensis, but was less effective against aerosol exposure. LVS faces regulatory hurdles that to date have prevented its licensure for general use. Therefore, a better defined and more effective vaccine is being sought. To this end we have created gene deletion mutants in the virulent subsp. tularensis strain and tested them for their ability to elicit a protective immune response against systemic or aerosol challenge with the highly virulent wild-type subsp. tularensis strain, SCHU S4. Both oral and intradermal (ID) primary vaccination routes were assessed in BALB/c and C3H/HeN mice as was oral boosting. One SCHU S4 mutant missing the heat shock gene, clpB, was significantly more attenuated than LVS whereas a double deletion mutant missing genes FTT0918 and capB was as attenuated as LVS. In general mice immunized with SCHU S4 Delta clpB were significantly better protected against aerosol challenge than mice immunized with LVS. A single ID immunization of BALB/c mice with SCHU S4 Delta clpB was at least as effective as any other regimen examined. Mice immunized with SCHU S4 Delta 0918 Delta capB were generally protected to a similar degree as mice immunized with LVS. A preliminary examination of immune responses to vaccination with LVS, SCHU S4 Delta clpB, or SCHU S4 Delta 0918 Delta capB provided no obvious correlate to their relative efficacies.
机译:土拉弗朗西斯菌亚种 tularensis 是人类的一种高毒力兼性细胞内病原体,也是一种潜在的生物武器。活疫苗株,F。 tularensis LVS是50年前开发的,它通过对弱毒性 holarctica 亚种菌株进行实用减毒来开发。 LVS被证明在暴露于具有完全毒性亚种的皮内攻击的人类志愿者中非常有效。 tularensis ,但对气雾剂的暴露效果较差。 LVS面临监管障碍,迄今为止,该障碍阻止了其一般使用许可。因此,正在寻求一种定义更好,更有效的疫苗。为此,我们在有毒亚种中创建了基因缺失突变体。 tularensis 菌株,并测试了它们对高毒力野生型亚种引起的针对全身或气溶胶攻击的保护性免疫应答的能力。 tularensis菌株SCHU S4。与口服加强免疫一样,在BALB / c和C3H / HeN小鼠中评估了口服和皮内(ID)初次接种途径。缺失热休克基因 clpB 的一个SCHU S4突变体比LVS显着减弱,而缺失了 FTT0918 和 capB 的双缺失突变体像LVS一样衰减。在一般情况下,用SCHU S4 Delta clpB 免疫的小鼠比用LVS免疫的小鼠能更好地抵抗气溶胶攻击。用SCHU S4 Delta clpB 对BALB / c小鼠进行单ID免疫至少与任何其他检查方案一样有效。用SCHU S4 Delta 0918 Delta capB 免疫的小鼠通常受到的保护程度与LVS免疫的小鼠相似。对LVS,SCHU S4 Delta clpB 或SCHU S4 Delta 0918 Delta capB 接种疫苗的免疫反应的初步检查提供了与它们的相对功效没有明显的相关性。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号